Form 4: BioMarin Executive Earns Restricted Stock Units Based on Performance

G. Eric Davis, EVP and Chief Legal Officer at BioMarin Pharmaceutical Inc., acquired restricted stock units (RSUs) based on the company's performance metrics between 2021 and 2023, as certified by the Board of Directors' Compensation Committee.

Summary

• G. Eric Davis, an executive at BioMarin Pharmaceutical Inc., has acquired RSUs based on the company's performance.
• The RSUs were earned based on a formula considering relative total shareholder return, strategic goals achieved, and non-GAAP income over the three-year period from 2021 to 2023.
• The Board of Directors' Compensation Committee certified the earning of these RSUs on February 27, 2024.
• The RSUs will vest on March 15, 2024, contingent upon Davis's continued service through that date.
• Davis now beneficially owns a total of 91,897 shares of common stock following the reported transactions.

Sentiment

Score: 7

Explanation: The document reflects a positive event for the executive, as they are receiving compensation based on company performance. It's a routine filing, but the underlying performance metrics suggest a degree of success.

Positives

• The earning of RSUs is tied to the company's performance, aligning executive compensation with shareholder interests.
• The performance metrics include shareholder return, strategic goals, and non-GAAP income, covering multiple aspects of the business.
• Davis's continued service is required for the RSUs to vest, incentivizing him to remain with the company.

Future Outlook

The RSUs will vest on March 15, 2024, subject to the reporting person's continued service through that date.

Industry Context

This filing is a routine disclosure of executive compensation in the pharmaceutical industry, where equity-based compensation is common to align management incentives with company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation is a standard practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize RSUs and stock options as part of their executive compensation packages.
• The specific metrics used to determine RSU grants (shareholder return, strategic goals, non-GAAP income) are common performance indicators in the industry.

Stakeholder Impact

• Shareholders may view the RSU grants positively, as they are tied to company performance.
• Employees may be motivated by the fact that executive compensation is linked to strategic goals and financial performance.

Key Dates